Clinical Trial
NCT03144999 Completed
Treatment of Advanced Dry Age Related Macular Degeneration With AAVCAGsCD59
A Phase 1, Open-Label, Multi-Center, Dose-Escalating, Safety and Tolerability Study of a Single Intravitreal Injection of AAVCAGsCD59 in Patients With Advanced Non-Exudative (Dry) Age-Related Macular Degeneration With Geographic Atrophy
Disease
Disease type
Other
Orphan drug recognition
Yes
Inclusion / Exclusion
Funding
private
Members involved
Others investigators
PD Dr Markus Preising
Representative
Germany
Pediatric Ophthalmology Rare Diseases (WG3), Research (TWG8), Retinal Rare Eye Diseases (WG1)
ERN EYE member investigating site
HCP : Principal investigators
Universitätsklinikum Gießen und Marburg GmbH, Gießen, Germany
Adress
Klinik und Poliklinik für Augenheilkunde Friedrichstr. 18
35392 Gießen
Germany